Status:
SUSPENDED
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Lead Sponsor:
Jerry Vockley, MD, PhD
Collaborating Sponsors:
Ultragenyx Pharmaceutical Inc
Conditions:
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently...
Detailed Description
Participation in the study will require three overnight admissions at the Clinical and Translational Research Center at the UPMC Children's Hospital of Pittsburgh (also called the PCTRC). The total le...
Eligibility Criteria
Inclusion
- A diagnosis of MCAD deficiency with molecular confirmation.
- Age criteria age ≥ 16 years
- Able to perform and comply with study activities including overnight admission to the research unit at UPMC Children's Hospital Pittsburgh, placement of an IV catheter, and all blood draws.
- Negative pregnancy test for all female subjects of child bearing age. Females of childbearning potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted.
- Signed informed consent for subjects ≥ 18 years, or assent by subjects age 16-17 years with parental consent for underaged subjects.
Exclusion
- Use of any investigational drug within 30 days of screening.
- Active infection (viral or bacterial) or any other intercurrent condition as reported by the subject or noted on physical exam at screening.
- Evidence of liver disease as defined by elevations of AST or ALT\> 1.5x ULN at screening
- Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study.
- Pregnant, planning to become pregnant, breastfeeding or lactating females.
- Diagnosis of pancreatic insufficiency or concomitant use of a pancreatic lipase inhibitor (e.g. Orlistat) which can interfere with absorption of triheptanoin
- Subjects with type 1 or type 2 diabetes, or who take medications as part of their routine care that can cause hypoglycemia
Key Trial Info
Start Date :
February 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06067802
Start Date
February 1 2026
End Date
July 1 2028
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224